Medicus Pharma Ltd Stock Performance
| MDCX Stock | USD 1.55 0.01 0.64% |
The company secures a Beta (Market Risk) of 0.59, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Medicus Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medicus Pharma is expected to be smaller as well. At this point, Medicus Pharma has a negative expected return of -0.51%. Please make sure to verify Medicus Pharma's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Medicus Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Medicus Pharma Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject in Patients with Gorlin Syndrome | 10/29/2025 |
2 | Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights | 11/14/2025 |
3 | Why Medicus Pharma Ltd. stock could see breakout soon - 2025 Support Resistance Free Weekly Watchlist of Top Performers - moha.gov.vn | 11/28/2025 |
4 | Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President | 12/01/2025 |
5 | Medicus Pharma Ltd. Enters Into 5.1 Million Warrant Inducement | 12/05/2025 |
6 | Medicus Pharma Ltd. Enters Into 5.1 Million Warrant Inducement - Coshocton Tribune | 12/11/2025 |
7 | Medicus Pharma Ltd. Completes Enrolment of Ninety Patients for Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 12/15/2025 |
8 | Why Medicus Pharma Ltd. stock could benefit from AI revolution - Market Movement Recap Weekly Consistent Profit Watchlists - | 12/19/2025 |
9 | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | 12/22/2025 |
10 | Dated alerts on Medicus Pharma withdrawn - marketscreener.com | 01/02/2026 |
Medicus Pharma Relative Risk vs. Return Landscape
If you would invest 232.00 in Medicus Pharma Ltd on October 13, 2025 and sell it today you would lose (77.00) from holding Medicus Pharma Ltd or give up 33.19% of portfolio value over 90 days. Medicus Pharma Ltd is currently does not generate positive expected returns and assumes 5.11% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of otc bb equitys are less volatile than Medicus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Medicus Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medicus Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc bb equitys, such as Medicus Pharma Ltd, and traders can use it to determine the average amount a Medicus Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0996
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MDCX |
Based on monthly moving average Medicus Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medicus Pharma by adding Medicus Pharma to a well-diversified portfolio.
Medicus Pharma Fundamentals Growth
Medicus OTC BB Equity prices reflect investors' perceptions of the future prospects and financial health of Medicus Pharma, and Medicus Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medicus OTC BB Equity performance.
| Return On Equity | -26.61 | ||||
| Return On Asset | -1.71 | ||||
| Current Valuation | 33.05 M | ||||
| Shares Outstanding | 24.71 M | ||||
| Price To Earning | (0.21) X | ||||
| Price To Book | 15.81 X | ||||
| EBITDA | (323.24 K) | ||||
| Net Income | (11.16 M) | ||||
| Cash And Equivalents | 1.22 K | ||||
| Total Debt | 2.51 M | ||||
| Current Ratio | 0.53 X | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (10.25 M) | ||||
| Earnings Per Share | (2.23) X | ||||
| Market Capitalization | 38.82 M | ||||
| Total Asset | 5.65 M | ||||
| Retained Earnings | (28.9 M) | ||||
| Working Capital | 3.07 M | ||||
About Medicus Pharma Performance
Evaluating Medicus Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medicus Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medicus Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.69) | (1.78) | |
| Return On Capital Employed | (3.85) | (4.04) | |
| Return On Assets | (1.69) | (1.78) | |
| Return On Equity | (3.90) | (4.09) |
Things to note about Medicus Pharma performance evaluation
Checking the ongoing alerts about Medicus Pharma for important developments is a great way to find new opportunities for your next move. OTC BB Equity alerts and notifications screener for Medicus Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medicus Pharma generated a negative expected return over the last 90 days | |
| Medicus Pharma has high historical volatility and very poor performance | |
| Medicus Pharma may become a speculative penny stock | |
| Medicus Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Medicus Pharma Ltd currently holds 2.51 M in liabilities. Medicus Pharma has a current ratio of 0.52, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Medicus Pharma's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (11.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medicus Pharma Ltd currently holds about 1.22 K in cash with (10.25 M) of positive cash flow from operations. | |
| Roughly 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Dated alerts on Medicus Pharma withdrawn - marketscreener.com |
- Analyzing Medicus Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medicus Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Medicus Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medicus Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medicus Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medicus Pharma's otc bb equity. These opinions can provide insight into Medicus Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medicus OTC BB Equity Analysis
When running Medicus Pharma's price analysis, check to measure Medicus Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicus Pharma is operating at the current time. Most of Medicus Pharma's value examination focuses on studying past and present price action to predict the probability of Medicus Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicus Pharma's price. Additionally, you may evaluate how the addition of Medicus Pharma to your portfolios can decrease your overall portfolio volatility.